The trial could target patients with established cardiovascular disease, heart failure, or diabetes,25,44 as well as individuals with signs of atrial cardiomyopathy, such as supraventricular ectopy, enlarged left atria, or elevated N-terminal prohormone of brain natriuretic peptide,45,46,47,48 and could also be assessed using clinical risk scores, such as the Cohorts for Heart and Aging Research in Genomic Epidemiology Model for Atrial Fibrillation risk score.49 Reduced tissue sodium could also plausibly be achieved through the use of sodium-glucose cotransporter 2 inhibitors.50 The gene discussed is SLC5A2; the disease is atrial fibrillation.